Hospices Civils de Lyon and Université Claude Bernard Lyon 1, Pierre Bénite 69495, France.
Best Pract Res Clin Haematol. 2011 Jun;24(2):257-70. doi: 10.1016/j.beha.2011.03.001. Epub 2011 May 10.
High-dose therapy followed by autologous stem cell transplantation is widely accepted as salvage therapy for patients with relapsed aggressive lymphoma. In the pre-rituximab era, autologous stem cell transplantation had also been increasingly applied as a consolidation treatment for patients with indolent lymphoma in second or subsequent remission whereas controversies have emerged concerning its role in first line therapy from several randomized trials. Broad development and amazing efficacy of monoclonal antibody-based combination therapies for de novo or relapsing follicular lymphoma patients render previous conclusions outdated and underline the critical need for further phase III trials. This review focuses on available data from pre-rituximab and rituximab eras to help clarifying the precise role and timing of autologous stem cell transplantation among the current armamentarium for follicular lymphoma treatment.
大剂量化疗联合自体造血干细胞移植被广泛认为是复发侵袭性淋巴瘤患者的挽救性治疗方法。在利妥昔单抗时代之前，自体造血干细胞移植也已越来越多地用于第二次或随后缓解的惰性淋巴瘤患者的巩固治疗，但几项随机试验对其在一线治疗中的作用提出了争议。基于单克隆抗体的联合治疗方案在新发或复发滤泡性淋巴瘤患者中的广泛发展和惊人疗效使得之前的结论过时，并强调了进一步进行 III 期试验的迫切需要。本综述重点关注利妥昔单抗应用前后的数据，以帮助阐明在滤泡性淋巴瘤治疗的现有治疗方案中，自体造血干细胞移植的确切作用和时机。
